Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Monte Rosa Therapeutics Inc | GLUE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.47 | 08:55:12 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.47 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.44 - 8.84 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 5.47 | USD |
Monte Rosa Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 274.34M | 50.15M | - | 0 | -135.35M | -2.70 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Monte Rosa Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLUE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.75 | 6.08 | 5.24 | 5.70 | 115,253 | -0.28 | -4.87% |
| 1 Month | 7.08 | 8.22 | 5.24 | 6.68 | 125,235 | -1.61 | -22.74% |
| 3 Months | 5.34 | 8.84 | 4.185 | 6.29 | 137,713 | 0.13 | 2.43% |
| 6 Months | 2.57 | 8.84 | 2.44 | 5.09 | 186,233 | 2.90 | 112.84% |
| 1 Year | 5.07 | 8.84 | 2.44 | 5.34 | 201,945 | 0.40 | 7.89% |
| 3 Years | 22.00 | 45.56 | 2.44 | 11.33 | 207,872 | -16.53 | -75.14% |
| 5 Years | 22.00 | 45.56 | 2.44 | 11.33 | 207,872 | -16.53 | -75.14% |
Monte Rosa Therapeutics Description
| Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. |
